

# Ahmed Idbaih

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/138765/publications.pdf>

Version: 2024-02-01

187  
papers

16,505  
citations

26610

56  
h-index

17090

122  
g-index

200  
all docs

200  
docs citations

200  
times ranked

19630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	3.8	1,619
2	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	3.8	982
3	Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. <i>Journal of Clinical Oncology</i> , 2009, 27, 4150-4154.	0.8	887
4	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
5	Primary brain tumours in adults. <i>Lancet</i> , The, 2012, 379, 1984-1996.	6.3	723
6	Genome-wide association study identifies five susceptibility loci for glioma. <i>Nature Genetics</i> , 2009, 41, 899-904.	9.4	713
7	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963.	13.9	670
8	Clinical trial of blood-brain barrier disruption by pulsed ultrasound. <i>Science Translational Medicine</i> , 2016, 8, 343re2.	5.8	529
9	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	13.7	374
10	IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Clinical Cancer Research</i> , 2010, 16, 1597-1604.	3.2	364
11	A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. <i>Brain</i> , 2010, 133, 973-982.	3.7	314
12	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <i>Nature Genetics</i> , 2017, 49, 789-794.	9.4	259
13	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAF <sup>V600E</sup> -Mutated Erdheim-Chester Disease. <i>Journal of Clinical Oncology</i> , 2015, 33, 411-418.	0.8	238
14	Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 3793-3801.	3.2	232
15	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 3307-3317.	3.2	230
16	MRI of Clot in Cerebral Venous Thrombosis. <i>Stroke</i> , 2006, 37, 991-995.	1.0	224
17	DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. <i>Cancer Cell</i> , 2015, 28, 307-317.	7.7	221
18	Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 5203-5211.	3.2	210

#	ARTICLE	IF	CITATIONS
19	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949.	0.6	165
20	Chromosome 7p11.2 (EGFR) variation influences glioma risk. <i>Human Molecular Genetics</i> , 2011, 20, 2897-2904.	1.4	158
21	Two types of chromosome 1p losses with opposite significance in gliomas. <i>Annals of Neurology</i> , 2005, 58, 483-487.	2.8	157
22	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology</i> , The, 2017, 18, e113-e125.	5.1	154
23	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	0.6	150
24	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017, 130, 1377-1380.	0.6	146
25	Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. <i>Molecular Cancer</i> , 2008, 7, 41.	7.9	145
26	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , 2016, 18, 388-400.	0.6	143
27	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495.	3.4	135
28	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2857-2865.	0.8	132
29	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. <i>Acta Neuropathologica</i> , 2017, 134, 691-703.	3.9	131
30	Clinical Spectrum of Encephalitis Associated With Antibodies Against the $\alpha$ -Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor. <i>JAMA Neurology</i> , 2015, 72, 1163.	4.5	123
31	Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. <i>Neuro-Oncology</i> , 2011, 13, 84-98.	0.6	115
32	A Hypermethylated Phenotype Is a Better Predictor of Survival than <i>MGMT</i> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. <i>Clinical Cancer Research</i> , 2011, 17, 7148-7155.	3.2	107
33	CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2019, 21, 1519-1528.	0.6	107
34	<i>MGMT</i> -STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. <i>Clinical Cancer Research</i> , 2013, 19, 5513-5522.	3.2	106
35	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. <i>Cancers</i> , 2021, 13, 47.	1.7	106
36	A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 5071-5080.	3.2	103

#	ARTICLE	IF	CITATIONS
37	BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. <i>International Journal of Cancer</i> , 2008, 122, 1778-1786.	2.3	100
38	ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. <i>Cancer Cell International</i> , 2010, 10, 1.	1.8	99
39	Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 328-336.	0.8	99
40	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. <i>American Journal of Hematology</i> , 2018, 93, E114-E117.	2.0	94
41	Enhanced antitumor efficacy of biocompatible magnetosomes for the magnetic hyperthermia treatment of glioblastoma. <i>Theranostics</i> , 2017, 7, 4618-4631.	4.6	93
42	Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. <i>Nature Biotechnology</i> , 2016, 34, 1161-1167.	9.4	91
43	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type Glioblastomas. <i>Clinical Cancer Research</i> , 2016, 22, 1185-1196.	3.2	89
44	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , 2016, 132, 625-634.	3.9	85
45	Blood-brain barrier, cytotoxic chemotherapies and glioblastoma. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1285-1300.	1.4	83
46	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology</i> , 2018, 19, 1170-1179.	5.1	80
47	Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. <i>Laboratory Investigation</i> , 2005, 85, 176-181.	1.7	79
48	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. <i>Nature Communications</i> , 2016, 7, 11263.	5.8	73
49	<i>IDH</i> -wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. <i>Neuro-Oncology</i> , 2021, 23, 955-966.	0.6	73
50	Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 87, 181-187.	1.4	70
51	Dramatic response of a <i>BRAF</i> V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. <i>Neurology</i> , 2014, 83, 1478-1480.	1.5	70
52	Molecular analysis of diffuse intrinsic brainstem gliomas in adults. <i>Journal of Neuro-Oncology</i> , 2014, 116, 405-411.	1.4	69
53	Diagnostic and prognostic value of preoperative combined GFAP, IGFBP2, and YKL40 plasma levels in patients with glioblastoma. <i>Cancer</i> , 2014, 120, 3972-3980.	2.0	69
54	Development of non-pyrogenic magnetosome minerals coated with poly-L-lysine leading to full disappearance of intracranial U87-Luc glioblastoma in 100% of treated mice using magnetic hyperthermia. <i>Biomaterials</i> , 2017, 141, 210-222.	5.7	69

#	ARTICLE	IF	CITATIONS
55	Emerging circulating biomarkers in glioblastoma: promises and challenges. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1311-1323.	1.5	60
56	Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. <i>Neuro-Oncology</i> , 2014, 16, 662-670.	0.6	59
57	Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: A prospective pilot study. <i>Pediatric Blood and Cancer</i> , 2004, 43, 55-58.	0.8	58
58	Histiocytosis. <i>Lancet, The</i> , 2021, 398, 157-170.	6.3	58
59	Molecular genetic markers as predictors of response to chemotherapy in gliomas. <i>Current Opinion in Oncology</i> , 2007, 19, 606-611.	1.1	56
60	Predictive and prognostic factors for gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 781-789.	1.1	54
61	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. <i>British Journal of Haematology</i> , 2018, 183, 608-617.	1.2	54
62	Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 33-41.	1.4	54
63	Genetic Risk Profiles Identify Different Molecular Etiologies for Glioma. <i>Clinical Cancer Research</i> , 2010, 16, 5252-5259.	3.2	53
64	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2021, 3, e784-e794.	5.9	52
65	Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2182-2192.	1.9	51
66	Genomic changes in progression of low-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 90, 133-140.	1.4	51
67	Prophylactic intrathecal chemotherapy in primary CNS lymphoma. <i>Journal of Neuro-Oncology</i> , 2012, 106, 143-146.	1.4	51
68	Deciphering the 8q24.21 association for glioma. <i>Human Molecular Genetics</i> , 2013, 22, 2293-2302.	1.4	50
69	Chains of magnetosomes with controlled endotoxin release and partial tumor occupation induce full destruction of intracranial U87-Luc glioma in mice under the application of an alternating magnetic field. <i>Journal of Controlled Release</i> , 2017, 262, 259-272.	4.8	50
70	Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas. <i>Neuro-Oncology</i> , 2012, 14, 1393-1403.	0.6	49
71	Therapeutic Application of Noncytotoxic Molecular Targeted Therapy in Gliomas: Growth Factor Receptors and Angiogenesis Inhibitors. <i>Oncologist</i> , 2008, 13, 978-992.	1.9	48
72	<i>IDH1</i> Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?. <i>Oncologist</i> , 2010, 15, 196-199.	1.9	48

#	ARTICLE	IF	CITATIONS
73	Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 83.	1.2	48
74	Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. <i>Neuro-Oncology</i> , 2013, 15, 542-547.	0.6	48
75	Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. <i>Neuro-Oncology</i> , 2014, 16, 1244-1254.	0.6	47
76	<i>FGFR1</i> actionable mutations, molecular specificities, and outcome of adult midline gliomas. <i>Neurology</i> , 2018, 90, e2086-e2094.	1.5	47
77	SLIT2/ROBO signaling in tumor-associated microglia and macrophages drives glioblastoma immunosuppression and vascular dysmorphia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	46
78	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , 2012, 60, 885-894.	1.6	44
79	CRX Is a Diagnostic Marker of Retinal and Pineal Lineage Tumors. <i>PLoS ONE</i> , 2009, 4, e7932.	1.1	43
80	TCF12 is mutated in anaplastic oligodendroglioma. <i>Nature Communications</i> , 2015, 6, 7207.	5.8	42
81	Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. <i>Acta Neuropathologica</i> , 2018, 135, 743-755.	3.9	42
82	ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 479-486.	1.4	41
83	Diagnostic and prognostic markers in gliomas. <i>Current Opinion in Oncology</i> , 2009, 21, 537-542.	1.1	40
84	Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. <i>European Journal of Cancer</i> , 2011, 47, 802-808.	1.3	39
85	An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. <i>Molecular Cancer</i> , 2010, 9, 234.	7.9	37
86	Quantifying the heritability of glioma using genome-wide complex trait analysis. <i>Scientific Reports</i> , 2015, 5, 17267.	1.6	37
87	Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. <i>Journal of Neuro-Oncology</i> , 2011, 105, 219-224.	1.4	36
88	TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas. <i>Journal of Neuro-Oncology</i> , 2014, 118, 131-9.	1.4	35
89	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. <i>Neurology</i> , 2015, 85, 1325-1331.	1.5	34
90	Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 13.	2.0	34

#	ARTICLE	IF	CITATIONS
91	Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. <i>Neuro-Oncology</i> , 2017, 19, now160.	0.6	33
92	Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic Challenges. <i>Oncologist</i> , 2020, 25, e1763-e1776.	1.9	33
93	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , 2021, 23, 1433-1446.	0.6	33
94	A novel tumor suppressor function of Kindlin-3 in solid cancer. <i>Oncotarget</i> , 2014, 5, 8970-8985.	0.8	33
95	Alpha $\beta$ -internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. <i>Cancer</i> , 2011, 117, 3014-3026.	2.0	32
96	A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries. <i>European Journal of Cancer</i> , 2020, 135, 130-146.	1.3	31
97	18F-FDG PET in neurodegenerative Langerhans cell histiocytosis. <i>Journal of Neurology</i> , 2008, 255, 575-580.	1.8	30
98	Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. <i>Neuropathology</i> , 2008, 28, 440-443.	0.7	29
99	Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. <i>Genome Biology</i> , 2014, 15, 471.	3.8	29
100	DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. <i>PLoS ONE</i> , 2012, 7, e38881.	1.1	28
101	Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab061.	0.4	28
102	Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. <i>Neuro-Oncology</i> , 2008, 10, 540-547.	0.6	27
103	Blood-brain barrier disruption in humans using an implantable ultrasound device: quantification with MR images and correlation with local acoustic pressure. <i>Journal of Neurosurgery</i> , 2020, 132, 875-883.	0.9	27
104	Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade. <i>Journal of Neuro-Oncology</i> , 2010, 97, 353-364.	1.4	26
105	Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 457-462.	1.4	26
106	Prognostic impact of the isocitrate dehydrogenase 1 single nucleotide polymorphism rs11554137 in malignant gliomas. <i>Cancer</i> , 2013, 119, 806-813.	2.0	26
107	SNP Array Analysis Reveals Novel Genomic Abnormalities Including Copy Neutral Loss of Heterozygosity in Anaplastic Oligodendrogliomas. <i>PLoS ONE</i> , 2012, 7, e45950.	1.1	25
108	Oligodendrogliomas. <i>Current Opinion in Oncology</i> , 2012, 24, 687-693.	1.1	24

#	ARTICLE	IF	CITATIONS
109	Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 347-358.	1.0	24
110	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. <i>Oncotarget</i> , 2016, 7, 21556-21569.	0.8	24
111	DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide. <i>PLoS ONE</i> , 2014, 9, e104455.	1.1	22
112	Molecular profiling of gliomas: potential therapeutic implications. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 955-962.	1.1	22
113	Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. <i>ESMO Open</i> , 2020, 5, e000672.	2.0	22
114	Central nervous system involvement in Erdheim-Chester disease. <i>Neurology</i> , 2020, 95, e2746-e2754.	1.5	22
115	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. <i>Journal of Neuro-Oncology</i> , 2011, 103, 221-230.	1.4	21
116	NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas. <i>PLoS ONE</i> , 2009, 4, e4107.	1.1	19
117	Changes in chromatin state reveal ARNT2 at a node of a tumorigenic transcription factor signature driving glioblastoma cell aggressiveness. <i>Acta Neuropathologica</i> , 2018, 135, 267-283.	3.9	19
118	Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF <sup>v600E</sup> -mutant ganglioglioma. <i>Neurology</i> , 2018, 91, 523-525.	1.5	19
119	Profiling Anti-Apoptotic BCL-xL Protein Expression in Glioblastoma Tumorspheres. <i>Cancers</i> , 2020, 12, 2853.	1.7	19
120	Tumor and Endothelial Cell Hybrids Participate in Glioblastoma Vasculature. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	18
121	Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. <i>CNS Oncology</i> , 2015, 4, 381-386.	1.2	18
122	Prognostic markers in gliomas. <i>Future Oncology</i> , 2010, 6, 733-739.	1.1	17
123	Biodegraded magnetosomes with reduced size and heating power maintain a persistent activity against intracranial U87-Luc mouse GBM tumors. <i>Journal of Nanobiotechnology</i> , 2019, 17, 126.	4.2	17
124	Predictive biomarkers investigated in glioblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 883-893.	1.5	16
125	Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. <i>Neuro-Oncology</i> , 2016, 18, 888-890.	0.6	16
126	Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas. <i>Brain Pathology</i> , 2017, 27, 567-579.	2.1	16



#	ARTICLE	IF	CITATIONS
127	5-Azacitidine in patients with IDH1/2-mutant recurrent glioma. <i>Neuro-Oncology</i> , 2020, 22, 1226-1228.	0.6	16
128	Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> <sup>V600E</sup> Mutant Adult Glial and Glioneuronal Tumors. <i>Neurology</i> , 2021, 97, e673-e683.	1.5	16
129	CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548. <i>Neuro-Oncology</i> , 2021, 23, vi55-vi56.	0.6	16
130	Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. <i>Cancer Genetics and Cytogenetics</i> , 2007, 176, 121-126.	1.0	15
131	TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 103-107.	1.0	15
132	Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. <i>Journal of Neuro-Oncology</i> , 2010, 100, 439-441.	1.4	15
133	Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations. <i>Oncologist</i> , 2019, 24, 1584-1592.	1.9	15
134	No association of MDM2 SNP309 with risk of glioblastoma and prognosis. <i>Journal of Neuro-Oncology</i> , 2007, 85, 241-244.	1.4	14
135	Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. <i>Frontiers in Oncology</i> , 2021, 11, 671972.	1.3	14
136	Array-Based Genomics in Glioma Research. <i>Brain Pathology</i> , 2010, 20, 28-38.	2.1	13
137	Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 400-408.	0.6	13
138	The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis. <i>Journal of Neurology</i> , 2014, 261, 1537-1543.	1.8	13
139	EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	13
140	Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide. <i>Journal of Neuro-Oncology</i> , 2015, 122, 273-281.	1.4	12
141	Prognosis of patients with primary malignant brain tumors admitted to the intensive care unit: a two-decade experience. <i>Journal of Neurology</i> , 2017, 264, 2303-2312.	1.8	12
142	Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. <i>Acta Neuropathologica Communications</i> , 2018, 6, 89.	2.4	12
143	Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading. <i>Oncogenesis</i> , 2020, 9, 11.	2.1	12
144	Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. <i>European Journal of Cancer</i> , 2021, 144, 162-168.	1.3	12

#	ARTICLE	IF	CITATIONS
145	Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist. <i>Cell Death and Disease</i> , 2021, 12, 647.	2.7	12
146	Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. <i>Brain Research</i> , 2008, 1198, 16-20.	1.1	11
147	Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. <i>Scientific Reports</i> , 2021, 11, 10176.	1.6	11
148	Heterogeneity of Response to Iron-Based Metalloids in Glioblastoma Is Associated with Differences in Chemical Structures and Driven by FAS Expression Dynamics and Transcriptomic Subtypes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10404.	1.8	11
149	Clinical Course and MRI Changes of Basilar Artery Dolichoectasia: Three Case Reports. <i>Cerebrovascular Diseases</i> , 2004, 17, 262-264.	0.8	10
150	Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status. <i>Journal of Neuro-Oncology</i> , 2008, 88, 185-188.	1.4	10
151	Dural Arteriovenous Fistula Mimicking a Brainstem Glioma. <i>Journal of Neuroimaging</i> , 2015, 25, 1053-1055.	1.0	10
152	Chromosome 17p Homodisomy Is Associated With Better Outcome in 1p19q Non-Codeleted and <i>IDH</i> -Mutated Gliomas. <i>Oncologist</i> , 2016, 21, 1131-1135.	1.9	10
153	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019, 92, e2754-e2763.	1.5	9
154	A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?. <i>Cancers</i> , 2020, 12, 3775.	1.7	9
155	Dramatic response of <i>STRN-NTRK</i> -fused malignant glioneuronal tumor to larotrectinib in adult. <i>Neuro-Oncology</i> , 2021, 23, 1200-1202.	0.6	9
156	An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	8
157	IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. <i>Neuro-Oncology</i> , 2018, 20, 716-718.	0.6	8
158	The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 175.	2.4	8
159	Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. <i>Cell Death and Disease</i> , 2021, 12, 763.	2.7	8
160	Altered cerebral glucose metabolism in an animal model of diabetes insipidus: A micro-PET study. <i>Brain Research</i> , 2007, 1158, 164-168.	1.1	7
161	Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106006.	0.6	7
162	PAK3 is a key signature gene of the glioma proneural subtype and affects its proliferation, differentiation and growth. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1257-1271.	2.1	7

#	ARTICLE	IF	CITATIONS
163	Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101. <i>Neuro-Oncology Practice</i> , 2022, 9, 310-316.	1.0	7
164	Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. <i>Journal of Neuro-Oncology</i> , 2015, 124, 385-392.	1.4	6
165	Basal Ganglia Germinoma in an Adult. <i>World Neurosurgery</i> , 2016, 92, 584.e11-584.e14.	0.7	6
166	Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. <i>Oncologist</i> , 2018, 23, 1500-1510.	1.9	6
167	Hybrid [18F]-F-DOPA PET/MRI Interpretation Criteria and Scores for Glioma Follow-up After Radiotherapy. <i>Clinical Neuroradiology</i> , 2022, 32, 735-747.	1.0	5
168	TP53 mutations but no CHEK2 <sup>Δ1100</sup> variant in familial gliomas. <i>Cancer Genetics and Cytogenetics</i> , 2009, 188, 126-128.	1.0	4
169	One-year survival of patients with high-grade glioma discharged alive from the intensive care unit. <i>Journal of Neurology</i> , 2021, 268, 516-525.	1.8	4
170	Mutational analysis of Rac2 in gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 87, 365-366.	1.4	3
171	Anaplastic oligodendrogliomas: value of early chemotherapy. <i>Nature Reviews Neurology</i> , 2013, 9, 7-8.	4.9	3
172	Novel molecular targets in treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2013, 9, 612-613.	4.9	3
173	Etiology and prognosis of acute respiratory failure in patients with primary malignant brain tumors admitted to the intensive care unit. <i>Journal of Neuro-Oncology</i> , 2019, 142, 139-148.	1.4	3
174	Expression and Prognostic Value of CD80 and CD86 in the Tumor Microenvironment of Newly Diagnosed Glioblastoma. <i>Canadian Journal of Neurological Sciences</i> , 2023, 50, 234-242.	0.3	3
175	Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124.	1.7	3
176	Eye movement abnormalities in neurodegenerative langerhans cell histiocytosis. <i>Neurological Sciences</i> , 2022, 43, 6539-6546.	0.9	3
177	Phenotypic selection through cell death: stochastic modelling of O-6-methylguanine-DNA methyltransferase dynamics. <i>Royal Society Open Science</i> , 2020, 7, 191243.	1.1	2
178	Descriptive and retrospective analysis of diffuse glioma patients with symptomatic SARS-CoV2 infection during the first wave of the pandemic. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab078.	0.4	2
179	Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 265-277.	1.5	1
180	Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 729-731.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. Case Reports in Endocrinology, 2019, 2019, 1-8.	0.2	1
182	Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials. European Journal of Cancer, 2022, 163, 98-107.	1.3	1
183	Precision medicine in glioblastoma therapy. Expert Review of Precision Medicine and Drug Development, 2016, 1, 451-468.	0.4	0
184	Neuro-oncology: A rapidly evolving multidisciplinary speciality. Presse Medicale, 2018, 47, e185-e186.	0.8	0
185	Role of multidrug resistance in glioblastoma chemoresistance: Focus on ABC transporters. , 2021, , 243-261.		0
186	ProgrÃ©s rÃ©cents dans la gÃ©nÃ©mique et dans le traitement mÃ©dical des gliomes cÃ©rÃ©braux. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 11-21.	0.0	0
187	Dural and osteolytic sarcomatoid relapse of a secondary gliosarcoma with tryptase immunoreactivity. , 2016, 35, 154-158.		0